Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ATF4 | P18848 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27778309 | 1.00 | HRH3 (0.57) | HRH3RAB9ANPC1CHRNA7CHRNB2 | |
| SCHEMBL14368768 | 0.85 | TAS1R3 (0.64) | HRH3CHRNA7CHRNB2CHRNA4POLB | |
| SCHEMBL14392352 | 0.78 | CHRNA7 (0.51) | RAB9ANPC1CHRNA7HTR3A | |
| SCHEMBL14368703 | 0.78 | CHRNA7 (0.51) | RAB9ANPC1CHRNA7HTR3A | |
| SCHEMBL27757300 | 0.78 | CHRNA7 (0.51) | RAB9ANPC1CHRNA7HTR3A | |
| SCHEMBL24225638 | 0.78 | RAB9A (0.73) | RAB9ANPC1L3MBTL1ATF4PTGES | |
| SCHEMBL17209555 | 0.78 | RAB9A (0.73) | RAB9ANPC1L3MBTL1ATF4PTGES | |
| SCHEMBL14368809 | 0.77 | F10 (0.49) | NPC1TAS1R3TAS1R1 | |
| SCHEMBL27778277 | 0.77 | F10 (0.49) | NPC1TAS1R3TAS1R1 | |
| SCHEMBL28783273 | 0.75 | POLB (0.58) | HRH3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101484442-A | Compounds that are agonists of muscarinic receptors and tha may be effective in treating pain, alzheimer's disease and/or schizophrenia | ASTRAZENECA AB (SE) | 2009-07-15 | — | — | CN | disclosed |
| WO-2007126362-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | HRH3 337/4885RAB9A 913/4885NPC1 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.